254 related articles for article (PubMed ID: 35806102)
1. Recent Advances in Renal Medullary Carcinoma.
Su Y; Hong AL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102
[TBL] [Abstract][Full Text] [Related]
2. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
3. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior.
Cheng JX; Tretiakova M; Gong C; Mandal S; Krausz T; Taxy JB
Mod Pathol; 2008 Jun; 21(6):647-52. PubMed ID: 18327209
[TBL] [Abstract][Full Text] [Related]
4. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
[TBL] [Abstract][Full Text] [Related]
5. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
Msaouel P; Tannir NM; Walker CL
Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
[TBL] [Abstract][Full Text] [Related]
6. Renal medullary carcinoma in a young mixed-race man in Japan.
Toriyama A; Izumi H; Tomita S; Nagashima Y; Ueda Y; Aoki Y; Tsujimura A; Yao T; Hino O
Pathol Int; 2019 Apr; 69(4):241-245. PubMed ID: 30843648
[TBL] [Abstract][Full Text] [Related]
7. [SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts].
Agaimy A; Hartmann A
Pathologe; 2021 Nov; 42(6):571-577. PubMed ID: 34609565
[TBL] [Abstract][Full Text] [Related]
8. Renal Medullary Carcinoma: a Report of the Current Literature.
Blas L; Roberti J; Petroni J; Reniero L; Cicora F
Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
[TBL] [Abstract][Full Text] [Related]
9. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
[TBL] [Abstract][Full Text] [Related]
10. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
[TBL] [Abstract][Full Text] [Related]
11. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas.
Tan KT; Kim H; Carrot-Zhang J; Zhang Y; Kim WJ; Kugener G; Wala JA; Howard TP; Chi YY; Beroukhim R; Li H; Ha G; Alper SL; Perlman EJ; Mullen EA; Hahn WC; Meyerson M; Hong AL
Genome Med; 2021 Jul; 13(1):114. PubMed ID: 34261517
[TBL] [Abstract][Full Text] [Related]
12. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
Vokshi BH; Davidson G; Tawanaie Pour Sedehi N; Helleux A; Rippinger M; Haller AR; Gantzer J; Thouvenin J; Baltzinger P; Bouarich R; Manriquez V; Zaidi S; Rao P; Msaouel P; Su X; Lang H; Tricard T; Lindner V; Surdez D; Kurtz JE; Bourdeaut F; Tannir NM; Davidson I; Malouf GG
Nat Commun; 2023 May; 14(1):3034. PubMed ID: 37236926
[TBL] [Abstract][Full Text] [Related]
13. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
Jia L; Carlo MI; Khan H; Nanjangud GJ; Rana S; Cimera R; Zhang Y; Hakimi AA; Verma AK; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE; Gartrell BA; Chen YB
Mod Pathol; 2019 Sep; 32(9):1329-1343. PubMed ID: 30980040
[TBL] [Abstract][Full Text] [Related]
14. SMARCB1/INI1 inactivation in renal medullary carcinoma.
Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
[TBL] [Abstract][Full Text] [Related]
15. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
[TBL] [Abstract][Full Text] [Related]
16. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.
Calderaro J; Masliah-Planchon J; Richer W; Maillot L; Maille P; Mansuy L; Bastien C; de la Taille A; Boussion H; Charpy C; Jourdain A; Bléchet C; Pierron G; Gentien D; Choudat L; Tournigand C; Delattre O; Allory Y; Bourdeaut F
Eur Urol; 2016 Jun; 69(6):1055-61. PubMed ID: 26433572
[TBL] [Abstract][Full Text] [Related]
17. SWI/SNF-deficient neoplasms of the genitourinary tract.
Sirohi D; Ohe C; Smith SC; Amin MB
Semin Diagn Pathol; 2021 May; 38(3):212-221. PubMed ID: 33840529
[TBL] [Abstract][Full Text] [Related]
18. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
Carter SA; Walker AN
J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
[TBL] [Abstract][Full Text] [Related]
19. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
